Zhiqiang Cao

Zhiqiang Cao

Auto-generated profile, based on publicly available information

Zhiqiang Cao

Beijing Key Laboratory of Surveillance, Early Warning and Pathogen Research on Emerging Infectious Diseases, Beijing Center for Disease Prevention and Control, 16 Hepingli Middle St, Dongcheng District, Beijing, 100013, China, 86 01064407095

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in Vaccine
Verified
Journal Article
Closed access
ZCZhiqiang Cao
Zhiqiang Cao
RYRui Yu
Rui Yu
QYQianli Yuan
Qianli Yuan
WJWenyan Ji
Wenyan Ji
XLXiaomei Li
Xiaomei Li
LSLuodan Suo
Luodan Suo

11 March 2026 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
DZDan Zhao
Dan Zhao
YMYing Ma
Ying Ma
JLJuan Li
Juan Li
XLXiaomei Li
Xiaomei Li
ZCZhiqiang Cao
Zhiqiang Cao
LSLuodan Suo
Luodan Suo
Background: A large wave of COVID-19 caused by SARS-CoV-2 Omicron subvariants began in Beijing in early December 2022. Objective: This study aimed to evaluate the COVID-19 vaccine effectiveness (VE) in mitigating the risk of COVID-19–related hospitalization during the epidemic. Methods: We conducted a retrospective cohort study linking regional health care data and vaccination registry routinely collected in Beijing. All electronic medical records on COVID-19–related hospital discharges of older inpatients aged ≥80 years during November 2022 and February 2023 were included. Poisson regressions were used to estimate incidence risk ratio of COVID-19–related hospitalization, severe or critical cases, and in-hospital death compared with unvaccinated groups, adjusting for gender and age. VE was calculated as 1 minus incidence risk ratio×100%. Results: A total of 53,789 individuals aged ≥80 years were included, 28,423 (52.84%) were male, 45,270 (84.16%) were aged 80‐89 years, and 8519 (15.84%) were aged ≥90 years. Overall, 30,531 (56.76%) were in the vaccine group, with 4524 (8.41%) of the total participants receiving partial vaccination, 20.91% completing the primary series, and 14,761 (27.44%) receiving one booster. Additionally, 23,258 (43.24%) were in the unvaccinated group. Of the 53,789 hospitalized individuals, 17,916 (33.31%) had a COVID-19 diagnosis, 3535 (6.57%) had COVID-19–related hospitalization, 961 (1.79%) were COVID-19 severe or critical cases, and 4130 (7.68%) had in-hospital death. The analysis revealed that the VE of booster vaccination in preventing COVID-19–related hospital, severe or critical COVID-19, and in-hospital death was 63.5% (95% CI 59.8%‐66.9%), 66.9% (95% CI 60.1%‐72.6%) and 79.4% (95% CI 77%‐81.5%), the VE of primary series 56% (95% CI 51.4%‐60.2%), 66.8% (95% CI 59%‐73%) and 66.4% (95% CI 63%‐69.5%). Conclusions: The first booster vaccination was associated with significantly reduced the risk of COVID-19–related severe outcomes in older inpatients aged ≥80 years during the Omicron-dominant period. Considering the potential selection bias and unmeasured confounders, these estimates may reflect both the VE and the better baseline health status of the vaccinated older individuals.

3 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LSLuodan Suo
Luodan Suo
JLJuan Li
Juan Li
FLFeng Lu
Feng Lu
LWLai Wei
Lai Wei
HXHui Xu
Hui Xu
PYPeng Yang
Peng Yang
Background Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) hospitalization in infants globally. While nirsevimab has shown effectiveness in typical 5–6 month seasons, evidence during prolonged seasons and under surveillance-guided immunization strategies is limited.Methods In this population-based retrospective cohort study in Beijing, China, 114,572 infants born between April 1, 2025, and March 31, 2026, were followed through a 9-month RSV season defined by real-time surveillance. A single dose of nirsevimab was administered via a voluntary, self-pay programme under the surveillance-guided strategy. Outcomes included RSV‑associated LRTI hospitalisation (primary), severe RSV‑associated LRTI (ICU admission or mechanical ventilation), and all‑cause LRTI hospitalisation (secondary). Effectiveness was estimated as (1 – adjusted incidence rate ratio) × 100% using Poisson regression, adjusting for birth cohort, age, sex, gestational age, birth weight, and receipt of self-paid vaccines. Pre-specified subgroup analyses were performed across the risk spectrum—including preterm and low-birthweight infants—by sex, age, birth cohort, gestational age, and birth weight, with interaction tests.Findings Of 114,572 eligible infants (87.8% aged ≤3 months; 51.8% male), 8,976 (7.8%) received nirsevimab. RSV-associated LRTI hospitalization occurred in 23 recipients (5.2 per 1,000 person-years) and 1,229 non-recipients (21.0 per 1,000 person-years), yielding 77.7% effectiveness (95% CI, 66.2–85.3; P < .001) and an absolute rate difference of 15.8 per 1,000 person-years. Effectiveness was 85.8% (95% CI, 42.1–96.5; P = .006) against severe RSV-associated LRTI and 39.0% (95% CI, 26.4–49.5; P < .001) against all-cause LRTI hospitalization. Protection was consistent across gestational age and birth weight subgroups despite substantially higher baseline rates in preterm and low-birthweight infants. Effectiveness varied by birth cohort (89.7% in catch-up vs 66.4% in seasonal; P for interaction = .010). Results were robust in sensitivity analyses.Interpretation During a prolonged season, nirsevimab provided substantial and durable protection against RSV-associated hospitalization under a surveillance-guided programme, supporting data-driven immunization timing in settings with unpredictable seasonality.Funding Capital's Funds for Health Improvement and Research (2026-1G-3012).